📊 SPRO Key Takeaways
Is Spero Therapeutics, Inc. (SPRO) a Good Investment?
Spero Therapeutics is a pre-commercial pharmaceutical company with minimal revenue (258K) and severe operating losses (net margin -2791.9%), indicating the business is not yet financially viable. While the strong balance sheet (56M cash, no debt) provides runway, the company is burning approximately 7.2M per period with no evidence of near-term profitability, making current fundamentals uninvestable despite improving loss trends.
Spero Therapeutics, Inc. Key Strengths (SPRO)
- Exceptional balance sheet with 56.1M cash representing 94.9% of total assets
- Zero long-term debt with 0.00x debt-to-equity ratio and minimal liabilities
- Improving loss trajectory with net losses declining 112.5% YoY, suggesting operational burn rate improvement
- Positive operating cash flow of 15.9M despite negative net income suggests potential non-operational cash inflows
SPRO Stock Risks: Spero Therapeutics, Inc. Investment Risks
- Pre-commercial stage with negligible revenue (258K) generating near-zero profitability metrics
- Severe operating losses of -7.5M with -2921.7% operating margin indicating business model is not yet operational
- Estimated 7-8 year cash runway at current burn rate, but no visible path to cash flow breakeven from disclosed fundamentals
- Pharmaceutical company model is entirely dependent on undisclosed clinical pipeline success rates and regulatory outcomes
Key Metrics to Watch
- Revenue growth trajectory and achievement of commercialization milestones
- Operating cash burn rate sustainability and timeline to profitability
- Cash balance and run-rate to assess remaining development runway
Spero Therapeutics, Inc. (SPRO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 6,148.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 10.50x current ratio provides a solid financial cushion.
SPRO Profit Margin, ROE & Profitability Analysis
SPRO vs Healthcare Sector: How Spero Therapeutics, Inc. Compares
How Spero Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Spero Therapeutics, Inc. Stock Overvalued? SPRO Valuation Analysis 2026
Based on fundamental analysis, Spero Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Spero Therapeutics, Inc. Balance Sheet: SPRO Debt, Cash & Liquidity
SPRO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Spero Therapeutics, Inc.'s revenue has grown significantly by 310% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.27 indicates the company is currently unprofitable.
SPRO Revenue Growth, EPS Growth & YoY Performance
SPRO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$7.2M | $-0.13 |
| Q3 2025 | N/A | -$7.4M | $-0.13 |
| Q2 2025 | N/A | -$1.7M | $-0.03 |
| Q1 2025 | $12.0K | -$12.7M | $-0.24 |
| Q3 2024 | $65.0K | N/A | $-0.06 |
| Q2 2024 | $114.0K | -$11.9M | $-0.23 |
| Q1 2024 | $140.0K | -$12.7M | $-0.24 |
| Q3 2023 | $1.1M | -$3.2M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Spero Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SPRO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Spero Therapeutics, Inc. (CIK: 0001701108)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SPRO
What is the AI rating for SPRO?
Spero Therapeutics, Inc. (SPRO) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SPRO's key strengths?
Claude: Exceptional balance sheet with 56.1M cash representing 94.9% of total assets. Zero long-term debt with 0.00x debt-to-equity ratio and minimal liabilities.
What are the risks of investing in SPRO?
Claude: Pre-commercial stage with negligible revenue (258K) generating near-zero profitability metrics. Severe operating losses of -7.5M with -2921.7% operating margin indicating business model is not yet operational.
What is SPRO's revenue and growth?
Spero Therapeutics, Inc. reported revenue of $258.0K.
Does SPRO pay dividends?
Spero Therapeutics, Inc. does not currently pay dividends.
Where can I find SPRO SEC filings?
Official SEC filings for Spero Therapeutics, Inc. (CIK: 0001701108) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SPRO's EPS?
Spero Therapeutics, Inc. has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SPRO's fundamental grade?
Based on our AI fundamental analysis in May 2026, Spero Therapeutics, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SPRO stock overvalued or undervalued?
Valuation metrics for SPRO: ROE of -13.6% (sector avg: 15%), net margin of -2,791.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SPRO's AI grade for 2026?
Our dual AI analysis gives Spero Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SPRO's free cash flow?
Spero Therapeutics, Inc.'s operating cash flow is $15.9M, with capital expenditures of $0.0. FCF margin is 6,148.8%.
How does SPRO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,791.9% (avg: 12%), ROE -13.6% (avg: 15%), current ratio 10.50 (avg: 2).